Skip to main content
SpringerLink
Log in

Transitions and Combination Therapy for Pulmonary Arterial Hypertension

  • Chapter
Pulmonary Hypertension

Part of the book series: Contemporary Cardiology™ ((CONCARD))

Abstract

Pulmonary arterial hypertension (PAH) is a progressive and often fatal disease. Currently available pharmacotherapies are often suboptimal when used singly, due to either a poor clinical response or a complication from the therapy. As a consequence, transitioning patients from one therapy to another or adding a therapy is a frequently encountered clinical conundrum. This chapter examines the rationale and limited data surrounding transitioning patients from one pharmacotherapy to another and combining individual therapies to produce an improvement in clinical outcomes. Much of the research discussed deals with animal models used to test combination therapies, as there are few clinical trials in human subjects, but this is rapidly changing, as a number of controlled trials are currently either in the planning stages or in progress. Transitions clearly have a role in enhancing the convenience and safety of pulmonary hypertension therapy for some patients. Combination therapy looks promising and may well represent the future of PAH pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12):896–903.

    Article  PubMed  CAS  Google Scholar 

  2. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106(12):1477–82.

    Article  PubMed  CAS  Google Scholar 

  3. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121(6):409–15.

    PubMed  CAS  Google Scholar 

  4. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial. Ann Intern Med 2000; 132(6):425–34.

    PubMed  CAS  Google Scholar 

  5. Falk A, Lookstein RA, Mitty HA. Flolan infusion interruption: A lethal complication during venous access. J Vasc Interv Radiol 2001; 12(5):667–8.

    Article  PubMed  CAS  Google Scholar 

  6. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension*. Chest 2002; 121(5):1561–5.

    Article  PubMed  CAS  Google Scholar 

  7. Hill N, Barst R, Vachiery JL, Zwicket D, Naeije R. Long-term follow-up to the effects of transitioning patients with pulmonary arterial hypertension from IV epoprostenol to SC treprostinil. Am J Respir Crit Care Med. A174, 2004.

    Google Scholar 

  8. Hill N, Barst RJ, Vachiery J-L, Zwicke D, Naeije R. Long-term follow-up to the effects of transitioning patients with pulmonary arterial hypertension from IV epoprostenol to SC treprostinil. Am J Respir Crit Care Med 2004; 169:A174.

    Google Scholar 

  9. Gomberg-Maitland M, Barst RJ, McLaughlin V, et al. Transition from intravenous epoprostenol to intravenous treprostinil for the treatment of pulmonary arterial hypertension (PAH). Proc Am Thorac Soc Abs Issue 2005; 2:A300.

    Google Scholar 

  10. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586–9.

    Article  PubMed  Google Scholar 

  11. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44(2):209–14.

    Article  PubMed  CAS  Google Scholar 

  12. Schenk P, Petkov V, Madl C, et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001; 119:296–300.

    Article  PubMed  CAS  Google Scholar 

  13. Suleman N, Frost A. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004; 126(3):808–15.

    Article  PubMed  CAS  Google Scholar 

  14. Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: A pilot study. Chest. 2006; 130:1471–80.

    Article  PubMed  Google Scholar 

  15. Schermuly R, Roehl A, Weissmann N, et al. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000; 292(2):512–20.

    PubMed  CAS  Google Scholar 

  16. Schermuly R, Ghofrani H, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999; 160:1500–6.

    PubMed  CAS  Google Scholar 

  17. Schermuly R, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281(6): L1361–8.

    PubMed  CAS  Google Scholar 

  18. Schermuly R, Krupnik E, Tenor H, et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001; 164(9):1694–700.

    PubMed  CAS  Google Scholar 

  19. Ghofrani H, Rose F, Schermuly R, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002; 30(11):2489–92.

    Article  PubMed  CAS  Google Scholar 

  20. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104(11):1218–22.

    Article  PubMed  CAS  Google Scholar 

  21. Ghofrani H, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136(7):515–22.

    PubMed  CAS  Google Scholar 

  22. Ikeda D, Tsujino I, Ohira H, Itoh N, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 2005; 45:286–9.

    Article  PubMed  Google Scholar 

  23. Schermuly R, Kreisselmeier K, Ghofrani H, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94(8):1101–8.

    Article  PubMed  CAS  Google Scholar 

  24. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169(1):34–8.

    Article  PubMed  Google Scholar 

  25. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123(4):1293–5.

    Article  PubMed  Google Scholar 

  26. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1):158–64.

    Article  PubMed  CAS  Google Scholar 

  27. Simmoneau G, Rubin LJ, Galie N, et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension (PAH). Proc Am Thorac Soc 2007; 4:A300.

    Google Scholar 

  28. Hill L, Pearl R. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999; 86(4):1160–4.

    PubMed  CAS  Google Scholar 

  29. Hermon M, Golej J, Burda G, Marx M, Trittenwein G, Pollak A. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. Artif Organs 1999; 23(11):975–8.

    Article  PubMed  CAS  Google Scholar 

  30. Nagamine J, Hill LL, Pearl R. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit Care Med 2000 Jul; 28(7):2420–4.

    Google Scholar 

  31. Skimming J, DeMarco V, Kadowitz P, Cassin S. Effects of zaprinast and dissolved nitric oxide on the pulmonary circulation of fetal sheep. Pediatr Res 1996; 39(2):223–8.

    Article  PubMed  CAS  Google Scholar 

  32. Deb B, Bradford K, Pearl R. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28(3):795–9.

    Article  PubMed  CAS  Google Scholar 

  33. Foubert L, De Wolf D, Mareels K, et al. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets. Pediatr Res 2002; 52(5):730–6.

    PubMed  CAS  Google Scholar 

  34. Foubert L, De Wolf D, Reyntjens K, et al. Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension. Anesth Analg 2003; 97(5):1497–500.

    Article  PubMed  CAS  Google Scholar 

  35. Ivy D, Ziegler J, Kinsella J, Wiggins J, Abman S. Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Chest 1998; 141(1 Suppl):17S.

    Article  Google Scholar 

  36. Atz A, Lefler A, Fairbrother D, Uber W, Bradley S. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002; 124(3):628–9.

    Article  PubMed  Google Scholar 

  37. Mychaskiw I, George, Sachdev V, Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001; 13(3):218–20.

    Article  PubMed  CAS  Google Scholar 

  38. Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003; 107(2):234–7.

    Article  PubMed  CAS  Google Scholar 

  39. Preston I, Hill N, Gambardella L, Warburton R, Klinger J. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med 2004; 229(9):920–5.

    CAS  Google Scholar 

  40. Schermuly R, Weissmann N, Enke B, et al. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: Synergism upon coapplication. Am J Respir Cell Mol Biol 2001; 25(2):219–25.

    PubMed  CAS  Google Scholar 

  41. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006; 129:417–25.

    Article  PubMed  Google Scholar 

  42. Christman B, McPherson C, Newman J, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327(2):70–5.

    PubMed  CAS  Google Scholar 

  43. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328(24):1732–9.

    Article  PubMed  CAS  Google Scholar 

  44. Ueno M, Miyauchi T, Sakai S, Yamauchi-Kohno R, Goto K, Yamaguchi I. A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. J Am Coll Cardiol 2002; 40(1):175–81.

    Article  PubMed  CAS  Google Scholar 

  45. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22(2):330–4.

    Article  PubMed  CAS  Google Scholar 

  46. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24(3):353–9.

    Article  PubMed  CAS  Google Scholar 

  47. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257–63

    Article  PubMed  Google Scholar 

  48. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006 Oct 3; 48(7):1433–7.

    Google Scholar 

  49. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qui C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 2006; 231:967–73.

    Google Scholar 

  50. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24(6):1007–10.

    Article  PubMed  CAS  Google Scholar 

  51. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469–75.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Todd Hirschtritt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kathryn Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas S. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center, Boston, MA

    Nicholas S. Hill MD

  2. Pulmonary Center, Boston University, Boston, MA

    Harrison W. Farber MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Hirschtritt, T., Steiner, M.K., Hill, N.S. (2008). Transitions and Combination Therapy for Pulmonary Arterial Hypertension. In: Hill, N.S., Farber, H.W. (eds) Pulmonary Hypertension. Contemporary Cardiology™. Humana Press. https://doi.org/10.1007/978-1-60327-075-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-075-5_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-661-0

  • Online ISBN: 978-1-60327-075-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation